Slide 1: Oral immunotherapy using antibodies
For personal use only Oral immunotherapy using antibodies Joe Baini, CEO 5 September 2011 2011 CONFIDENTIAL – Immuron 1
Slide 2: Forward Looking Statement
For personal use only FORWARD LOOKING STATEMENT This presentation and Immuron’s accompanying comments and explanations may include forward‐looking statements including statements containing words such as “may”, “expect”, “believe”, and “intend”, and may describe opinions about future events. We have
Slide 3: Table of Contents
Table of Contents For personal use only Section I •Brief Company Overview Section II •Key Strategies and Targets Section III •The Roadmap 2011 CONFIDENTIAL – Immuron 3
Slide 4: Section I: Company Overview
For personal use only Section I COMPANY OVERVIEW 2011 CONFIDENTIAL – Immuron 4
Slide 5: About Immuron
About Immuron For personal use only • Melbourne based, biopharmaceutical company (ASX: IMC) • Market Cap~24M • R&D at Hadassah Medical Center Israel, Uni. Melb. & Monash Uni. • Focuses on Oral Immunotherapy using dairy‐derived antibodies • Developed and patented a cost effective method to harvest po
Slide 6: The Immuron Advantage
The Immuron Advantage For personal use only Oral Immunotherapy Using Antibodies Oral immunotherapy using dairy‐derived polyclonal antibodies for metabolic & infectious diseases, oncology, and additional indications Strong Intellectual Property Immuron owns 7 patent families that protect its product
Slide 7: For personal use only
For personal use only 2010 2011 2012 2013 Travelan 1st partner Consolidate/ 10+ Markets Significant Expand Globally Revenue INFLUENZA Mice/Ferrets End preclinical/ Consolidate trials/ Reg/Partners/ Commence Ph. 1 Commercial production Launch! NASH Ph. 1/2a IND/Ph. 2b protocol Commence 2b/ License/ S
Slide 8: Section II: Key Strategies and Targets
For personal use only Section II KEY STRATEGIES AND TARGETS 2011 CONFIDENTIAL – Immuron 8
Slide 9: Adding Value/Decreasing Risk
Adding Value/Decreasing Risk For personal use only $/€ Commercial COMMERCIAL VALUE Risk Development Commercialisation Immuron Nycomed Meda New partners Research Hadassah U Melbourne Monash U TIME 2011 CONFIDENTIAL – Immuron 9
Slide 10: Product Pipeline
Product Pipeline For personal use only Indication Research` Pre‐Clinical Phase I Phase II Phase III Market Traveller’s Diarrhea Metabolic Syndrome / NASH (IMM‐124E) Influenza (IMM‐255) 2013/14 Clostridium difficile infection HIV (IMM‐243 & IMM‐252) Hepatic Carcinoma Others 2011 CONFIDENTIAL – Immuro
Slide 11: Key Strategies
Key Strategies For personal use only •Aggressively increase revenue through ramp-up of global partners/sales of Travelan I •Driving development of revolutionary influenza product (IMM-255) II towards a commercial-ready product in 2-3 years. •NASH: accelerating development & license opportunities. Si
Slide 12: Travelan - Market Expansion
For personal use only TRAVELAN ‐ MARKET EXPANSION 2011 CONFIDENTIAL – Immuron 12
Slide 13: Travellers' Diarrhoea
Travellers’ Diarrhoea For personal use only • Travellers’ Diarrhoea (TD) is the most common health condition facing travellers • Research shows that up to 50% of people who travel to developing countries will develop the problem • Typically characterized by stomach cramps, diarrhoea, fever and nause
Slide 14: Travelan - Immuron's product in the market
Travelan – Immuron’s product in the market For personal use only • Antibodies directed against bacteria that cause travellers’ diarrhoea • TGA approved, sales in Australia • Unique preventative oral immune therapeutic • Seeking steep sales growth. Global market ~US$650m+ pa • Exclusively licensed to
Slide 15: www.travelan.com.au
www.travelan.com.au For personal use only 2011 CONFIDENTIAL – Immuron 15
Slide 16: Influenza (IMM 255) - Accelerate: 2013/14
For personal use only INFLUENZA (IMM 255) – ACCELERATE: 2013/14 2011 CONFIDENTIAL – Immuron 16
Slide 17: Influenza
Influenza For personal use only • Direct medical costs in US – $10.4B pa* • 3‐5m cases pa of severe illness • Over 500,000 deaths worldwide pa • Influenza is the 8th leading cause of American deaths *Molinari et al. The annual impact of seasonal influenza in the US: Measuring disease burden and cost
Slide 18: IMM-255 - Clinical Development Roadmap
IMM‐255 – Clinical Development Roadmap For personal use only Initial trials were very effective in identifying the protective action of Immuron’s antibodies against infection by the H1N1 human virus Following the above positive results additional ferret trials were approved IMM‐255 to be developed f
Slide 19: Revolutionizing the Treatment of Influenza
Revolutionizing the Treatment of Influenza For personal use only IMM 255 is being designed as the world’s first dual‐acting and all‐natural oral therapy that can both: Oral Antibody IMM 255 + Colostrum Derived Adjuvants Passive immunity, inhibiting the Boosts the immune system to fight influenza inf
Slide 20: IMM-255 - Immuron's Solution to Influenza
IMM‐255 – Immuron’s Solution to Influenza For personal use only Antibodies designed to cope with the rapidly changing strains of flu as virus evolves (advantage of polyclonal antibodies) Convenience of an easily Aiming for world’s first accessible OTC therapy – not dual‐acting orally requiring a doc
Slide 21: Commercial Strategy
Commercial Strategy For personal use only Q4 2011 Q4 2012 Q4 2013 Preparation of Commercial vaccine seed stock production of anti‐ for commercial production influenza HIC Carry out further Carry out clinical clinical trials (if Product Launch trials needed) 2011 CONFIDENTIAL – Immuron 21
Slide 22: NASH (IMM-124E) - File IND
For personal use only NASH (IMM‐124E) ‐ FILE IND 2011 CONFIDENTIAL – Immuron 22
Slide 23: NASH - a major epidemic of the 21st Century
NASH – a major epidemic of the 21st Century For personal use only NCID predicts: Over 25m Americans will have NASH by 2025 NO approved treatment for NASH by either the FDA or the European Medicines Agency Demand for off‐label use, expected to be US$3.2bn at 2016 (however ineffective) Positive & enco
Slide 24: IMM-124E - Immuron's Solution for NASH
IMM‐124E – Immuron’s Solution for NASH For personal use only Orally administrated treatment Results to date very positive: Safe Trending of all parameters in the desirable direction Could be on the Addresses inflammatory market in mechanism less than 4 years Pursuing commencement of Phase 2b clinica
Slide 25: IMM-124E - Highlights and Next Steps
IMM‐124E – Highlights and Next Steps For personal use only Immuron is developing a therapy for NASH utilizing HIC IP The therapy uses similar platform technology as Travelan, incorporating the anti‐LPS antibodies The plan is now to proceed to a Phase 2b trial and a Phase 3 trial in 2013 Proposed tha
Slide 26: Section III: The Road Map
For personal use only Section III THE ROAD MAP 2011 CONFIDENTIAL – Immuron 26
Slide 27: Key Strategies
Key Strategies For personal use only •Aggressively increase revenue through ramp-up of global partners/sales of Travelan I •Driving development of revolutionary influenza product (IMM-255) II towards a commercial-ready product in 2-3 years. •NASH: accelerating development & license opportunities. Se
Slide 28: For personal use only
For personal use only 2010 2011 2012 2013 Travelan 1st partner Consolidate/ 10+ Markets Significant Expand Globally Revenue INFLUENZA Mice/Ferrets End preclinical/ Consolidate trials/ Reg/Partners/ Commence Ph. 1 Commercial production Launch! NASH Ph. 1/2a IND/Ph. 2b protocol Commence 2b/ License/ S
Slide 29: Immuron's Leadership: Management
Immuron’s Leadership: Management For personal use only Joe Baini, CEO • Experienced biotechnology executive; former GM for Gilead Sciences & non‐exec chairman for Avexa Ltd Dr Grant Rawlin, Chief Scientific Officer • Registered veterinary surgeon; extensive experience in regulatory affairs and R&D M
Slide 30: Immuron's Leadership: Board
Immuron’s Leadership: Board For personal use only Prof. Colin Chapman, Chairman • Professional Fellow at the Australian Health Workforce Institute, University of Melbourne. Key role in establishment of Acrux. Emeritus professor and Immediate past Dean, Faculty of Pharmacy and Pharmaceutical Sciences
Slide 31: Summary - Thank You
Summary For personal use only Thank You www.immuron.com www.travelan.com.au 2011 CONFIDENTIAL – Immuron 31